Trial TCTR20210923012
Publication Puthanakit T, Vaccine: X, 2022
Primary outcome on the report: GMRs of sVNT against Delta variant and anti-S-RBD IgG-wild type at 14 days after primary vaccination series of each group using SV3w/PZ30 as the reference arm.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.